asco.org2 天
About ASCO
Founded in 1964, the American Society of Clinical Oncology is the world's leading professional organization for physicians and oncology professionals caring for people with cancer.
asco.org2 天
Current practices and attitudes in menstrual management in adolescents with cancer: A ...
This material on this page is ©2025 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please ...
asco.org2 天
Phase 3 study of durvalumab combined with oleclumab or monalizumab in patients with ...
This material on this page is ©2025 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please ...
asco.org2 天
Phase 1/2 study of the selective TRK inhibitor larotrectinib in pediatric patients with cancer.
This material on this page is ©2025 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please ...
asco.org2 天
Larotrectinib long-term efficacy and safety in adult patients (pts) with tropomyosin ...
This material on this page is ©2025 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please ...
asco.org2 天
Activity and safety of larotrectinib in adult patients with TRK fusion cancer: An expanded ...
This material on this page is ©2025 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please ...
asco.org2 天
Clinical impact of targetable gene alterations on therapeutic outcomes in stage II/III ...
This material on this page is ©2025 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please ...
asco.org2 天
A phase I study of JS001, a humanized IgG4 mAb against programmed death-1 (PD-1) in ...
This material on this page is ©2025 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please ...
asco.org2 天
Safety, pharmacokinetics (PK), and clinical efficacy of ICP-723, a highly selective next ...
This material on this page is ©2025 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please ...
asco.org2 天
First-time in-human study of VMD-928, an allosteric and irreversible TrkA selective ...
This material on this page is ©2025 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please ...
asco.org2 天
Efficacy and safety of larotrectinib in pediatric patients with tropomyosin receptor kinase ...
This material on this page is ©2025 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please ...